HOUSTON, Sept. 17, 2020 /PRNewswire/ -- Marker
Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced that its President and Chief Executive Officer,
Peter L. Hoang, will present at the
upcoming Virtual Oppenheimer Fall Healthcare Life Sciences &
MedTech Summit on Tuesday, September 22,
2020.
CONFERENCE DETAILS
Virtual Oppenheimer Fall Healthcare Life Sciences &
MedTech Summit
Date: Tuesday,
Sept. 22, 2020
Time: 1:40-2:20 p.m. ET
Live webcasts of the presentation will be accessible from
the Investors section of the company's website
at markertherapeutics.com and will be available
for replay following the event.
About Marker Therapeutics, Inc.
Marker
Therapeutics, Inc. is a clinical-stage immuno-oncology company
specializing in the development of next-generation T cell-based
immunotherapies for the treatment of hematological malignancies and
solid tumor indications. Marker's cell therapy technology is based
on the selective expansion of non-engineered, tumor-specific T
cells that recognize tumor associated antigens (i.e. tumor targets)
and kill tumor cells expressing those targets. This population of T
cells is designed to attack multiple tumor targets following
infusion into patients and to activate the patient's immune system
to produce broad spectrum anti-tumor activity. Because Marker does
not genetically engineer its T cell therapies, we believe that our
product candidates will be easier and less expensive to
manufacture, with reduced toxicities, compared to current
engineered CAR-T and TCR-based approaches, and may provide patients
with meaningful clinical benefit. As a result, Marker believes its
portfolio of T cell therapies has a compelling product profile, as
compared to current gene-modified CAR-T and TCR-based
therapies.
To receive future press releases via email, please visit:
https://www.markertherapeutics.com/email-alerts.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-virtual-oppenheimer-fall-healthcare-life-sciences--medtech-summit-301132782.html
SOURCE Marker Therapeutics, Inc.